Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Electromed (ELMD) Gains from Sales and Divestitures (2015 - 2025)

Electromed (ELMD) reported Gains from Sales and Divestitures of $87500.0 for Q2 2025, up 118.56% year-over-year from $40034.0 in Q2 2024, and little changed on a QoQ basis from $87500.0 in Q4 2024.

Electromed (ELMD) has 11 years of Gains from Sales and Divestitures data on file, last reported at $87500.0 in Q2 2025.

  • Quarterly Gains from Sales and Divestitures rose 118.56% year-over-year to $87500.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $87500.0 (up 118.56% YoY) and the FY2025 annual result came in at $87500.0, up 118.56% from the prior year.
  • Gains from Sales and Divestitures steadied at $87500.0 in Q2 2025 per ELMD's latest filing, from $87500.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $87500.0 in Q3 2024 and bottomed at $40034.0 in Q2 2024.
  • The 5-year median for Gains from Sales and Divestitures is $45219.0 (2022), against an average of $61951.0.
  • The widest annual swing landed in 2024, when Gains from Sales and Divestitures declined 11.34%; it then jumped 118.56% in 2025.
  • Tracing ELMD's Gains from Sales and Divestitures over 5 years: stood at $40752.0 in 2021, then grew by 10.96% to $45219.0 in 2022, then fell by 0.15% to $45152.0 in 2023, then jumped by 93.79% to $87500.0 in 2024, then changed by 0.0% to $87500.0 in 2025.
  • Per Business Quant, the three latest ELMD Gains from Sales and Divestitures figures stand at $87500.0 (Q2 2025), $87500.0 (Q4 2024), and $87500.0 (Q3 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Electromed 300.53 Mn 283.55 Mn 14.64 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 87,500.00
Jun 30, 2025 87,500.00
Dec 31, 2024 87,500.00
Dec 31, 2024 87,500.00
Sep 30, 2024 87,500.00
Sep 30, 2024 87,500.00
Jun 30, 2024 40,034.00
Jun 30, 2024 40,034.00
Jun 30, 2023 45,152.00
Jun 30, 2023 45,152.00
Jun 30, 2022 45,219.00
Jun 30, 2022 45,219.00
Jun 30, 2021 40,752.00
Jun 30, 2021 40,752.00
Jun 30, 2020 45,833.00
Jun 30, 2020 45,833.00
Jun 30, 2019 40,000.00
Jun 30, 2019 40,000.00
Jun 30, 2018 40,000.00
Jun 30, 2018 40,000.00
Jun 30, 2017 33,056.00
Jun 30, 2017 33,056.00
Jun 30, 2016 -33,256.00
Jun 30, 2016 -33,256.00
Jun 30, 2015 19,605.00
Jun 30, 2015 19,605.00